Coronavirus Notebook: Leading Vaccines Near Approval, EU Signs More Advance Purchase Deals
Developers Are Under Pressure To Share Their IP And Reveal Costs
Executive Summary
Health activists are stepping up the pressure on COVID-19 vaccine companies to share their IP and reveal their costs, while the European Medicines Agency has published regulatory guidance advising vaccine developers to aim for a point estimate of efficacy of at least 50%.